
    
      Phase 2 study in approximately thirty subjects previously diagnosed with Polycythemia Vera
      who require phlebotomy on a routine basis. There is a 16 week dose finding phase followed by
      a dose stabilization phase. Subjects who successfully complete dose stabilization will be
      entered into a 12 week randomized withdrawal phase to confirm the response. Subsequently
      patients will enter into a 1 year open label extension to investigate long term safety.
    
  